In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Depuy's Strategy for a New Orthopedics Market

Executive Summary

As managed care makes its presence felt, the question orthopedic companies face isn't whether to deal with the new players or not, but how to navigate a market sending decidedly mixed signals.

You may also be interested in...



Dynamic Stabilization Rocks Spine

In the US acceptance of dynamic stabilization devices (DYNs) has been strong owing to the compelling advantages of DYNs over artificial discs, including that they can be implanted from a posterior route, do not violate the disc space and the procedure is reversible. Rather being an alternative to fusion, artificial discs will likely compete with DYNs.

In Spine, A Flurry of Deals

A conservative industry, orthopedics rarely sees a lot of acquisition activity. But a number of deals among spine companies recently underscores how hot the spine market is right now and the importance of acquisition as a strategy for realizing its potential.

Alvotech FDA Approval Clears Path To Challenge Humira

Alvotech and US marketing partner Teva can now launch “imminently” their long-planned rival to Humira, with the firms believing that the Simlandi biosimilar will stand out from the crowd of other adalimumab challengers thanks to a unique combination of product attributes.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel